Research ExplorerPublicationsDiscordance in Human Epidermal Growth Factor Receptor 2 (HER...

Discordance in Human Epidermal Growth Factor Receptor 2 (HER2) Phenotype Between Primary Tumor and Circulating Tumor Cells in Women With HER2-Negative Metastatic Breast Cancer

Standard

Discordance in Human Epidermal Growth Factor Receptor 2 (HER2) Phenotype Between Primary Tumor and Circulating Tumor Cells in Women With HER2-Negative Metastatic Breast Cancer. / de Gregorio, Amelie; Friedl, Thomas W. P.; Huober, Jens; Scholz, Christoph; de Gregorio, Nikolaus; Rack, Brigitte; Trapp, Elisabeth; Alunni-Fabbroni, Marianna; Riethdorf, Sabine; Muller , Volkmar ; Schneeweiss, Andreas; Pantel, Klaus; Meier-Stiegen, Franziska; Jaeger, Bernadette; Hartkopf, Andreas; Taran, Florin-Andrei; Fasching, Peter A; Janni, Wolfgang; Fehm, Tanja.

In: JCO PRECIS ONCOL, Vol. 2017, No. 1, 2017, p. 1-12.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

de Gregorio, A, Friedl, TWP, Huober, J, Scholz, C, de Gregorio, N, Rack, B, Trapp, E, Alunni-Fabbroni, M, Riethdorf, S, Muller , V, Schneeweiss, A, Pantel, K, Meier-Stiegen, F, Jaeger, B, Hartkopf, A, Taran, F-A, Fasching, PA, Janni, W & Fehm, T 2017, 'Discordance in Human Epidermal Growth Factor Receptor 2 (HER2) Phenotype Between Primary Tumor and Circulating Tumor Cells in Women With HER2-Negative Metastatic Breast Cancer', JCO PRECIS ONCOL, vol. 2017, no. 1, pp. 1-12. https://doi.org/10.1200/PO.17.00023

APA

de Gregorio, A., Friedl, T. W. P., Huober, J., Scholz, C., de Gregorio, N., Rack, B., Trapp, E., Alunni-Fabbroni, M., Riethdorf, S., Muller , V., Schneeweiss, A., Pantel, K., Meier-Stiegen, F., Jaeger, B., Hartkopf, A., Taran, F-A., Fasching, P. A., Janni, W., & Fehm, T. (2017). Discordance in Human Epidermal Growth Factor Receptor 2 (HER2) Phenotype Between Primary Tumor and Circulating Tumor Cells in Women With HER2-Negative Metastatic Breast Cancer. JCO PRECIS ONCOL, 2017(1), 1-12. https://doi.org/10.1200/PO.17.00023

Vancouver

de Gregorio A, Friedl TWP, Huober J, Scholz C, de Gregorio N, Rack B et al. Discordance in Human Epidermal Growth Factor Receptor 2 (HER2) Phenotype Between Primary Tumor and Circulating Tumor Cells in Women With HER2-Negative Metastatic Breast Cancer. JCO PRECIS ONCOL. 2017;2017(1):1-12. https://doi.org/10.1200/PO.17.00023

Bibtex

@article{f3f5b1b9b78c4b2e9b79d35f5ee0b905,
title = "Discordance in Human Epidermal Growth Factor Receptor 2 (HER2) Phenotype Between Primary Tumor and Circulating Tumor Cells in Women With HER2-Negative Metastatic Breast Cancer",
abstract = "PurposeDiscordance in human epidermal growth factor receptor 2 (HER2) status between primary tumor and metastases might have important implications for treatment response and therapy decisions. Here, we evaluate both the frequency of circulating tumor cells (CTCs) and the factors predicting HER2 discordance between primary tumor and CTCs as a potential surrogate for tumor biology and tumor heterogeneity in patients with metastatic breast cancer.Patients and MethodsThe number of CTCs in 7.5 mL of peripheral blood and HER2 status were evaluated in 1,123 women with HER2-negative metastatic breast cancer. HER2 discordance was defined as the presence of at least one CTC with a strong immunocytochemical HER2 staining intensity. Factors predicting discordance in HER2 phenotype were assessed using multivariable logistic regression.ResultsOverall, 711 (63.3%) of 1,123 screened patients were positive for CTCs (≥ one CTC). Discordance in HER2 phenotype between primary tumor and CTCs was observed in 134 patients (18.8%) and was significantly associated with histologic type (lobular v ductal; odds ratio [OR], 2.67; 95% CI, 1.63 to 4.39; P < .001), hormone receptor status (positive v negative; OR, 2.84; 95% CI, 1.15 to 7.02; P = .024), and CTC number (≥ five v one to four; OR, 7.64; 95% CI, 3.97 to 14.72; P < .001).ConclusionHER2 discordance between primary tumor and CTCs was observed in 18.8% of patients and was associated with histologic type, hormone receptor status of the primary tumor, and CTC number. The clinical utility of CTCs as liquid biopsy to assess tumor heterogeneity of metastatic disease and guide treatment decisions must be evaluated in prospective randomized trials.",
author = "{de Gregorio}, Amelie and Friedl, {Thomas W. P.} and Jens Huober and Christoph Scholz and {de Gregorio}, Nikolaus and Brigitte Rack and Elisabeth Trapp and Marianna Alunni-Fabbroni and Sabine Riethdorf and Volkmar Muller and Andreas Schneeweiss and Klaus Pantel and Franziska Meier-Stiegen and Bernadette Jaeger and Andreas Hartkopf and Florin-Andrei Taran and Fasching, {Peter A} and Wolfgang Janni and Tanja Fehm",
year = "2017",
doi = "10.1200/PO.17.00023",
language = "English",
volume = "2017",
pages = "1--12",
journal = "JCO PRECIS ONCOL",
issn = "2473-4284",
publisher = "American Society of Clinical Oncology",
number = "1",

}

RIS

TY - JOUR

T1 - Discordance in Human Epidermal Growth Factor Receptor 2 (HER2) Phenotype Between Primary Tumor and Circulating Tumor Cells in Women With HER2-Negative Metastatic Breast Cancer

AU - de Gregorio, Amelie

AU - Friedl, Thomas W. P.

AU - Huober, Jens

AU - Scholz, Christoph

AU - de Gregorio, Nikolaus

AU - Rack, Brigitte

AU - Trapp, Elisabeth

AU - Alunni-Fabbroni, Marianna

AU - Riethdorf, Sabine

AU - Muller , Volkmar

AU - Schneeweiss, Andreas

AU - Pantel, Klaus

AU - Meier-Stiegen, Franziska

AU - Jaeger, Bernadette

AU - Hartkopf, Andreas

AU - Taran, Florin-Andrei

AU - Fasching, Peter A

AU - Janni, Wolfgang

AU - Fehm, Tanja

PY - 2017

Y1 - 2017

N2 - PurposeDiscordance in human epidermal growth factor receptor 2 (HER2) status between primary tumor and metastases might have important implications for treatment response and therapy decisions. Here, we evaluate both the frequency of circulating tumor cells (CTCs) and the factors predicting HER2 discordance between primary tumor and CTCs as a potential surrogate for tumor biology and tumor heterogeneity in patients with metastatic breast cancer.Patients and MethodsThe number of CTCs in 7.5 mL of peripheral blood and HER2 status were evaluated in 1,123 women with HER2-negative metastatic breast cancer. HER2 discordance was defined as the presence of at least one CTC with a strong immunocytochemical HER2 staining intensity. Factors predicting discordance in HER2 phenotype were assessed using multivariable logistic regression.ResultsOverall, 711 (63.3%) of 1,123 screened patients were positive for CTCs (≥ one CTC). Discordance in HER2 phenotype between primary tumor and CTCs was observed in 134 patients (18.8%) and was significantly associated with histologic type (lobular v ductal; odds ratio [OR], 2.67; 95% CI, 1.63 to 4.39; P < .001), hormone receptor status (positive v negative; OR, 2.84; 95% CI, 1.15 to 7.02; P = .024), and CTC number (≥ five v one to four; OR, 7.64; 95% CI, 3.97 to 14.72; P < .001).ConclusionHER2 discordance between primary tumor and CTCs was observed in 18.8% of patients and was associated with histologic type, hormone receptor status of the primary tumor, and CTC number. The clinical utility of CTCs as liquid biopsy to assess tumor heterogeneity of metastatic disease and guide treatment decisions must be evaluated in prospective randomized trials.

AB - PurposeDiscordance in human epidermal growth factor receptor 2 (HER2) status between primary tumor and metastases might have important implications for treatment response and therapy decisions. Here, we evaluate both the frequency of circulating tumor cells (CTCs) and the factors predicting HER2 discordance between primary tumor and CTCs as a potential surrogate for tumor biology and tumor heterogeneity in patients with metastatic breast cancer.Patients and MethodsThe number of CTCs in 7.5 mL of peripheral blood and HER2 status were evaluated in 1,123 women with HER2-negative metastatic breast cancer. HER2 discordance was defined as the presence of at least one CTC with a strong immunocytochemical HER2 staining intensity. Factors predicting discordance in HER2 phenotype were assessed using multivariable logistic regression.ResultsOverall, 711 (63.3%) of 1,123 screened patients were positive for CTCs (≥ one CTC). Discordance in HER2 phenotype between primary tumor and CTCs was observed in 134 patients (18.8%) and was significantly associated with histologic type (lobular v ductal; odds ratio [OR], 2.67; 95% CI, 1.63 to 4.39; P < .001), hormone receptor status (positive v negative; OR, 2.84; 95% CI, 1.15 to 7.02; P = .024), and CTC number (≥ five v one to four; OR, 7.64; 95% CI, 3.97 to 14.72; P < .001).ConclusionHER2 discordance between primary tumor and CTCs was observed in 18.8% of patients and was associated with histologic type, hormone receptor status of the primary tumor, and CTC number. The clinical utility of CTCs as liquid biopsy to assess tumor heterogeneity of metastatic disease and guide treatment decisions must be evaluated in prospective randomized trials.

U2 - 10.1200/PO.17.00023

DO - 10.1200/PO.17.00023

M3 - SCORING: Journal article

VL - 2017

SP - 1

EP - 12

JO - JCO PRECIS ONCOL

JF - JCO PRECIS ONCOL

SN - 2473-4284

IS - 1

ER -